[go: up one dir, main page]

FR3081328B1 - Composition d'immunoglobulines humaines concentrees - Google Patents

Composition d'immunoglobulines humaines concentrees Download PDF

Info

Publication number
FR3081328B1
FR3081328B1 FR1854412A FR1854412A FR3081328B1 FR 3081328 B1 FR3081328 B1 FR 3081328B1 FR 1854412 A FR1854412 A FR 1854412A FR 1854412 A FR1854412 A FR 1854412A FR 3081328 B1 FR3081328 B1 FR 3081328B1
Authority
FR
France
Prior art keywords
composition
human immunoglobulins
concentrated human
immunoglobulins
concentrated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1854412A
Other languages
English (en)
Other versions
FR3081328A1 (fr
Inventor
Cecile Jaume
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Priority to FR1854412A priority Critical patent/FR3081328B1/fr
Priority to EP19737817.7A priority patent/EP3802589A1/fr
Priority to US17/056,626 priority patent/US20210205452A1/en
Priority to MX2020012486A priority patent/MX2020012486A/es
Priority to PCT/FR2019/051195 priority patent/WO2019224498A1/fr
Priority to CN201980034213.7A priority patent/CN112154154A/zh
Publication of FR3081328A1 publication Critical patent/FR3081328A1/fr
Application granted granted Critical
Publication of FR3081328B1 publication Critical patent/FR3081328B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention propose l'utilisation d'une composition pharmaceutique comprenant 200 g/L d'immunoglobulines G (IgG), entre 200 et 250 mM de glycine et entre 15 et 25 ppm de détergent non ionique particulièrement adaptée à une administration par voie sous-cutanée. Le pH de la composition est en outre compris entre 4,6 et 5,0.
FR1854412A 2018-05-24 2018-05-24 Composition d'immunoglobulines humaines concentrees Active FR3081328B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1854412A FR3081328B1 (fr) 2018-05-24 2018-05-24 Composition d'immunoglobulines humaines concentrees
EP19737817.7A EP3802589A1 (fr) 2018-05-24 2019-05-23 Composition d'immunoglobulines humaines concentrées
US17/056,626 US20210205452A1 (en) 2018-05-24 2019-05-23 Composition of Concentrated Human Immunoglobulins
MX2020012486A MX2020012486A (es) 2018-05-24 2019-05-23 Composicion de inmunoglobulinas humanas concentradas.
PCT/FR2019/051195 WO2019224498A1 (fr) 2018-05-24 2019-05-23 Composition d'immunoglobulines humaines concentrées
CN201980034213.7A CN112154154A (zh) 2018-05-24 2019-05-23 浓缩的人免疫球蛋白组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1854412 2018-05-24
FR1854412A FR3081328B1 (fr) 2018-05-24 2018-05-24 Composition d'immunoglobulines humaines concentrees

Publications (2)

Publication Number Publication Date
FR3081328A1 FR3081328A1 (fr) 2019-11-29
FR3081328B1 true FR3081328B1 (fr) 2021-01-01

Family

ID=64049309

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1854412A Active FR3081328B1 (fr) 2018-05-24 2018-05-24 Composition d'immunoglobulines humaines concentrees

Country Status (6)

Country Link
US (1) US20210205452A1 (fr)
EP (1) EP3802589A1 (fr)
CN (1) CN112154154A (fr)
FR (1) FR3081328B1 (fr)
MX (1) MX2020012486A (fr)
WO (1) WO2019224498A1 (fr)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
FR2853551B1 (fr) * 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
FR2940617B1 (fr) * 2008-12-30 2012-04-20 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobulines g
MY157239A (en) * 2009-05-27 2016-05-13 Baxalta Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
FR2961107B1 (fr) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
FR2962650B1 (fr) * 2010-07-19 2013-04-05 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
EP2537864B1 (fr) * 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Variantes Fc dotées de fonctions effectrices réduites
FR2995213A1 (fr) * 2012-09-12 2014-03-14 Lfb Biotechnologies Seringue contenant une composition, notamment pharmaceutique, comprenant des immunoglobulines, son procede de fabrication et son utilisation
US9085618B2 (en) * 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20160250329A1 (en) * 2013-10-29 2016-09-01 Albumedix A/S Antibody composition
FR3018450B1 (fr) * 2014-03-11 2016-04-15 Lab Francais Du Fractionnement Procede de preparation de proteines plasmatiques humaines
WO2016022377A2 (fr) * 2014-08-05 2016-02-11 Abbvie Inc. Méthodes de modulation du profil de glycosylation de protéines recombinées à l'aide d'oxygène dissous
FR3045387A1 (fr) * 2015-12-18 2017-06-23 Lab Francais Du Fractionnement Composition d’immunoglobulines humaines concentrees

Also Published As

Publication number Publication date
MX2020012486A (es) 2021-04-28
FR3081328A1 (fr) 2019-11-29
EP3802589A1 (fr) 2021-04-14
US20210205452A1 (en) 2021-07-08
CN112154154A (zh) 2020-12-29
WO2019224498A1 (fr) 2019-11-28

Similar Documents

Publication Publication Date Title
CL2020002162S1 (es) Bomba extractora de leche. (divisional solicitud 201902752)
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
PH12021550974A1 (en) Stablized pre-fusion rsv f proteins
EP4058484A4 (fr) Protéines de liaison à l'antigène ciblant des néoantigènes partagés
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
MY206022A (en) Anti-rsv monoclonal antibody formulation
WO2019005817A3 (fr) Clones d'hybridomes, anticorps monoclonaux dirigés contre vsig-4, et leurs procédés de fabrication et d'utilisation
MA54975B1 (fr) Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
EP3823986A4 (fr) Utilisation d'anticorps dirigés contre une famille à similarité de séquence 19, élément a5, pour le traitement de la douleur neuropathique
TN2018000341A1 (en) ANTl-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF.
MX2022005256A (es) Inhibidores de cd73.
MA53765B2 (fr) Tubulysines et conjugués tubulysines-protéines
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
FR3081328B1 (fr) Composition d'immunoglobulines humaines concentrees
DK1765337T3 (da) Kombination af tenofovir, ritonavir og TMC114
WO2022023566A3 (fr) Anticorps anti-cd-3 pour le traitement du coronavirus
WO2018170236A9 (fr) Inhibiteurs de cdpk1, compositions et procédés associés
EA202092694A1 (ru) Системы и способы количественного определения и модификации вязкости белков
UA45673S (uk) 1.-6. малюнок для опаковання «axa musli»
EA202190836A1 (ru) Антитела и антигенсвязывающие фрагменты против гликопротеина шипов sars-cov-2
MA51717A1 (fr) Anticorps anti-cd63, conjugués et leurs utilisations
CL2021003444A1 (es) Objetivo inmunológico no vírico
UA47064S (uk) 1.-2. чашка; 3. графин
CL2020001530S1 (es) Bomba extractora de leche. (divisional solicitud 202001352)

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20191129

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

CA Change of address

Effective date: 20221108

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8